Median survival extended by 5.7 months! Roche (RHHBY.US) emerges victorious in direct showdown with its new lung cancer drug, providing a major catalyst for its oncology business.

智通财经2026/10/26 03:06

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Zhitong Finance APP, Swiss healthcare and pharmaceutical giant Roche’s investigational lung cancer drug divarasib extended the median survival of patients by nearly six months compared to competing therapies in a late-stage clinical trial, potentially further strengthening the Swiss pharmaceutical company’s oncology treatment portfolio.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Median survival extended by 5.7 months! Roche (RHHBY.US) emerges victorious in direct showdown with its new lung cancer drug, providing a major catalyst for its oncology business.

You may also like

Crypto prices